Rexam Healthcare is expanding its La Verpillière site near Lyon, France, which since 2008 has produced subsets of an insulin injection pen for Eli Lilly and Co. Rexam's site specializes in drug administration systems, such as inhalers for asthma and injection devices, and houses Rexam Healthcare’s European Technology Center.
The expansion will add a building with approximately 2400 sq meters of cleanroom exclusively dedicated to the Eli Lilly and Co. project. Four years ago, Rexam first expanded the site to support the project, with plans to double in size by the end of 2013. The project represents an investment of about €M15 over a three-year period, Rexam reports in a press release.
According to Rexam, this new insulin injection pen for the treatment of diabetes has two subsets: the dose selection mechanism, and the protective cap. The glass cartridge filled with insulin that is inserted in the pen is produced by the Eli Lilly and Co. group at its Fegersheim site near Strasbourg. This is also where the two subsets are assembled and the insulin cartridge inserted.
The components of the injection pen will be manufactured by a fleet of dedicated robots including injection presses, marking machines, assembly line with ultrasound welding, and packaging technology, Rexam reports in the press release. Each phase will be controlled by a camera system.
For more information on Rexam Healthcare, which has 14 factories across three continents, visit www.rexam.com .